iBio Inc IBIO 深 滬
等待開盤 09-25 09:30:00 美东时间
1.205
-0.040
-3.21%
華盛通- 最 高1.25
- 今 開1.25
- 成交量 26.36万股
- 最 低 1.20
- 昨 收 1.245
- 總市值 7749.02万
- 52周最高 3.82
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.7811
- 委 比 -47.79%
- 總股本 6430.73万
- 歷史最高 17400.00
- 量 比 0.26
- 振 幅 4.02%
- 歷史最低 0.5562
- 每 手 1
- 風險率 0.50%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 赛富时获多家机构上调目标价，最高至300美元！谷歌获看多至450美元，仍有3成上涨空间
今日重点评级关注：Canaccord Genuity：维持Generac Holdings"买入"评级，目标价从275美元升至375美元；巴克莱：维持Oscar Health"超配"评级，目标价从39美元升至49美元
09-18 16:18
HC Wainwright & Co. Initiates Coverage On iBio with Buy Rating, Announces Price Target of $7
HC Wainwright & Co. analyst Ananda Ghosh initiates coverage on iBio (NASDAQ:IBIO) with a Buy rating and announces Price Target of $7.
09-17 18:11
iBio Highlights Breakthrough Antibody Strategy for Obesity
An announcement from Ibio ( ($IBIO) ) is now available. In September 2026, iBio...
09-15 05:53
iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer
iBio, Inc. appoints Dr. Molly Carr as Chief Medical Officer to strengthen its clinical-stage cardiometabolic pipeline. Dr. Carr, with over 30 years of experience in endocrinology and metabolic diseases, will lead global clinical strategy, medical affairs, and regulatory initiatives. She previously held senior roles at Eli Lilly and Company, GlaxoSmithKline, and others. Her expertise will support the advancement of iBio’s obesity and cardiometabol...
08-04 11:00
iBio Updates Governance Deadlines for 2026 Annual Meeting
Ibio ( ($IBIO) ) has shared an update. iBio, Inc. has scheduled its 2026 Annual...
07-18 05:31
iBio Announces New Preclinical Data From Obese Non-Human Primate Study Evaluating IBIO-610, Activin E Antibody Candidate
Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approach When combined with semaglutide, IBIO-610 drove greater visceral and total fat loss while reducing lean mass loss by 73% versus semaglutide alone Full...
07-01 19:08
iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study
iBio's IBIO-610, a first-in-class Activin E antibody, demonstrated up to 98% inhibition of active Activin E over eight weeks in non-human primate studies. When combined with semaglutide, it enhanced fat loss while preserving lean mass, reducing lean mass loss by 73% compared to semaglutide alone. These findings highlight its potential as a long-acting, differentiated therapy for obesity. Full data will be presented at the 2026 EASD Annual Meeting...
07-01 11:00
美股大行评级 | 存储再获看多！美光、闪迪、西部数据获机构上调目标价；次新股Cerebras、Blackstone、EagleRock获多家机构首予买入平均
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从5.25美元升至5.5美元；Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从9美元升至9.25美元
06-09 11:33
iBio to Participate in Upcoming Healthcare Investor Conferences
iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing therapies for obesity, cardiometabolic, and cardiopulmonary diseases, announced that its CEO and CSO, Martin Brenner, DVM, Ph.D., and CFO, Felipe Duran, will participate in the Jefferies Global Healthcare Conference on June 4, 2026, in New York, and the Leerink Partners Therapeutics Forum: I&I and Metabolism Conference in Boston from July 14–15, 2026. The Jefferies prese...
06-02 20:01
iBio Begins Human Testing of Obesity Drug Candidate, First Patient Dosed in Company's Initial Clinical Trial
iBio, Inc. (NASDAQ:IBIO) ("iBio" or the "Company"), a clinical-stage AI-driven innovator developing therapies for cardiometabolic and cardiopulmonary diseases and obesity, today announced the dosing of the first
06-02 19:04
